Gene
RAD51C
RAD51C is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (16), Actionable biomarkers (1), Trial mentions (103), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention RAD51C. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 10 of 8,738 | 0.11% | not measured | |
| 2025 | 9 of 8,875 | 0.10% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 8 of 8,275 | 0.10% | 18 of 11,460 | 0.16% |
| 2022 | 18 of 8,285 | 0.22% | 29 of 13,598 | 0.21% |
| 2021 | 12 of 8,692 | 0.14% | 22 of 15,045 | 0.15% |
| 2020 | 11 of 7,640 | 0.14% | 10 of 14,459 | 0.07% |
| 2019 | 13 of 7,300 | 0.18% | 14 of 12,159 | 0.12% |
| 2018 | 6 of 6,927 | 0.09% | 11 of 11,854 | 0.09% |
| 2017 | 4 of 6,558 | 0.06% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
Assay-provider ledger (16)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BIO-RAD Laboratories S.A. (trypan blue) | Reagent supplier | Analytical validation | 1 | May 18, 2026 |
| Fred Hutchinson Cancer Center | Not a company | Analytical validation | 1 | May 18, 2026 |
| JBS Biosciences | Reagent supplier | Analytical validation | 1 | May 18, 2026 |
| LGC Clinical Diagnostics | Reagent supplier | Analytical validation | 1 | May 18, 2026 |
| National Institute of Standards and Technology | Not a company | Analytical validation | 1 | May 18, 2026 |
Showing 5 of 16 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| RAD51C oncogenic mutation | Parp Inhibitors | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
Trial mentions (103)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07532434 | Trial biospecimen (AACT) |
| NCT04890613 | Trial eligibility (AACT) |
| NCT05732129 | Trial eligibility (AACT) |
| NCT07832630 | Trial eligibility (AACT) |
| NCT03047135 | Trial eligibility (AACT) |
Showing 5 of 103 trial mentions.
Target-disease associations (392)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX sex reversal 1 | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 392 associations.
Vendor sourcing (411)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001158025.4 |
| Abramson Cancer Center | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Prior treatment with a PARP inhibitor, ipilimumab, or other cytotoxic T-lymphocyte-associated-4 protein (CTLA-4) inhibitor. * Patients who have demonstr... | View trial NCT06747845 |
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Eastern Cooperative Oncology (ECOG) performance status of 0 to 1 * Diagnosis of a metastatic or locally advanced solid tumor malignancy for which no cur... | View trial NCT07832630 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | RAD51C | View trial NCT07832630 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | RAD51C | View trial NCT06747845 |
Showing 5 of 411 sourcing records.
Trial-cited literature (139)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer. | JAMA network open | 2025 | 4 |
| LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. | JCO precision oncology | 2025 | 2 |
| First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Nature medicine | 2024 | 130 |
| Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | 68 |
Showing 5 of 139 papers.
Protein variant mentions (164)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A126T | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
| p.A139V | 1 | 2015 | PMID 25741868 |
| p.A155T | 1 | 2015 | PMID 25741868 |
| p.A184T | 1 | 2015 | PMID 25741868 |
| p.A279G | 1 | 2015 | PMID 25741868 |
Showing 5 of 164 variants.
Literature-extracted relations (21)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. | 2025 |
| Neoplasms | Disease | associate |
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. | 2024 |
| Neoplasms | Disease | associate |
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. | 2023 |
| Breast Neoplasms | Disease | associate |
Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. | 2022 |
| Breast Neoplasms | Disease | associate |
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on <i>RAD51C</i>, <i>RAD51D</i>, <i>BARD1</i> updates to tumour pathology and cancer incidence. | 2022 |
Showing 5 of 21 relation assertions.
Organizations publishing (293)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 13 | 2015 to 2024 |
| University of Washington | Academic | 11 | 2015 to 2025 |
| Dana-Farber Cancer Institute | Other | 8 | 2015 to 2025 |
| Government of the United States of America | Government | 7 | 2012 to 2023 |
| Guy's and St Thomas' NHS Foundation Trust | Hospital | 7 | 2018 to 2025 |
Showing 5 of 293 organizations.
Where RAD51C appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- immune system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
366 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.